The next frontier of brain injury litigation: biomarker evidence
March 23, 2026
The defense expert leans forward and says the words every trial lawyer handling a brain injury case has heard before: "The MRI is normal."
For decades, that single sentence has shaped the trajectory of traumatic brain injury litigation. Today, we have the technology to challenge that narrative: neuroscience biomarkers.
The symptoms are real and often life-altering. Yet proving brain injury has historically been difficult when CT scans and MRIs appear "normal." Defense experts have long relied on that gap—arguing that symptoms are subjective, exaggerated, or unrelated to the event. Blood-based neurological biomarkers are now providing objective biochemical evidence of brain injury that can support diagnosis, causation, and long-term damages.
The historical challenge
The legal system favors objective evidence. Broken bones appear on X-rays. Spinal injuries show up on MRI scans. Surgical procedures leave clear documentation. Brain injuries, however, often do not.
Mild and moderate TBIs can produce profound neurological symptoms—memory loss, cognitive dysfunction, emotional changes, headaches, and fatigue—while traditional imaging shows little visible damage. This disconnect has historically allowed defense experts to minimize or dismiss legitimate brain injuries. Biomarker science is beginning to close that gap.
Biomarkers transforming brain injury evidence
Neurological research has identified several biomarkers detectable through blood testing that correlate with brain injury.
| Biomarker | What it measures | Relevance |
|---|---|---|
| GFAP | Glial cell damage | FDA-cleared; rises quickly after head trauma — useful in mild-to-moderate TBI evaluation |
| Neurofilament light chain (NfL) | Axonal injury | Elevated levels indicate nerve fiber damage and ongoing neurological impairment |
| APOE genotyping | Genetic recovery risk | APOE ε4 carriers face significantly worse recovery and higher long-term neurodegenerative risk |
| p-Tau217 | Neurodegenerative processes | Emerging marker linking acute concussions to long-term neurological decline |
Why this matters in litigation
For years, defense strategies have focused on labeling brain injuries as subjective complaints unsupported by objective findings. Laboratory evidence demonstrating measurable neurological damage makes that argument far more difficult to sustain. The conversation shifts — instead of debating whether an injury exists, the focus moves to the severity of the injury and the long-term impact on the patient's life. Jurors tend to place significant weight on medical testing, and when laboratory data confirms brain injury, the credibility of the claim strengthens substantially.
Emerging impact on case outcomes
Although biomarker testing is still developing in litigation, early case trends suggest it may significantly influence case valuation.
| Injury severity | Typical outcomes without biomarkers | Outcomes with biomarkers |
|---|---|---|
| Mild TBI | $50K – $150K | $200K – $650K+ |
| Moderate TBI | $150K – $500K | $750K – $3M+ |
| Severe TBI | $500K – $1.5M | $2M – $10M+ |
Every case is unique. Biomarker evidence is one factor shaping how cases are evaluated in mediation and trial.
Strategic considerations for attorneys
Many biomarkers peak shortly after injury, making early testing critical.
Chain of custody and reliable laboratory protocols are essential for evidentiary use.
Neuropsychological testing, treating physician testimony, and medical records remain central. Biomarker data strengthens that framework.
Because the science is relatively new, attorneys must clearly explain biomarker evidence to mediators and juries.
The future of brain injury litigation
Brain injuries are moving from subjective symptoms to measurable science—and when invisible injuries become visible through objective evidence, the conversation in the courtroom inevitably changes. As this science evolves, biomarker testing will likely become an increasingly common component of brain injury case development.
